cyclopentenylcytosin
cecyd
broadspectrum
antivir
agent
activ
dna
virus
herp
cytomegalo
pox
vaccinia
rna
virus
picorna
polio
coxsacki
rhino
toga
sindbi
semliki
forest
corona
rna
virus
orthomyxo
influenza
paramyxo
parainfluenza
measl
arena
junin
tacarib
rhabdo
vesicular
stomat
r
rna
virus
reo
cecyd
potent
antivir
agent
satur
counterpart
cyclopentylcytosin
carbodin
ccyd
cecyd
also
potent
cytocid
activ
number
tumor
cell
line
put
target
enzym
antivir
antitumor
action
cecyd
assum
ctp
synthetas
convert
utp
ctp
keep
hypothesi
find
antivir
cytocid
effect
cecyd
readili
revers
cyd
lesser
extent
urd
nucleosid
dthd
dcyd
contrast
pyrazofurin
two
nucleosid
analogu
assum
interfer
omp
decarboxylas
anoth
enzym
involv
biosynthesi
pyrimidin
ribonucleotid
potenti
cytocid
activ
cecyd
cecyd
pursu
combin
omp
decarboxylas
inhibitor
therapeut
potenti
treatment
viral
neoplast
diseas
variou
pyrimidin
nucleosid
analogu
ie
e
deoxi
fluoro
darabinofuranonh
n
n
n
syl
cytosin
known
potent
antivir
antitumor
agent
make
nucleosid
analogu
resist
degrad
nucleosid
ho
phosphorylas
cleav
nglycosid
bond
carbocycl
deriv
nucleosid
synthes
wherebi
sugar
part
replac
cycloalkyl
ring
rule
carbocycl
hodi
ho
deriv
retain
part
antitumor
oh
ho
oh
antivir
activ
parent
compound
also
carbocycl
analog
cyclopentyl
cyclocecyd
ccyd
pentenyl
deriv
normal
nucleosid
fig
formula
cyclopentenylcytosin
cecyd
cytidin
prepar
deriv
cyclopentylcytosin
ccyd
carbocycl
cytidin
term
ccyd
carbodin
cecyd
respect
carbodin
cecyd
shown
antitumor
activ
sever
human
tumor
xenograft
athym
mice
viho
prove
activ
herpesvirus
herp
ccyd
cecyd
assum
interact
simplex
cytomegalo
varicellazost
vaccinia
ctp
synthetas
enzym
convert
utp
influenza
vesicular
stomat
viru
japanes
ctp
phosphol
enceph
viru
punta
toro
viru
intraeliuiarli
direct
measur
ctp
synthetas
correspond
address
murin
leukemia
cell
indic
rega
institut
medic
research
minderbroedersstraat
cecyd
inde
inhibitori
leuven
belgium
enzym
deplet
ctp
pool
present
address
toyo
jozo
co
shibaura
result
inhibitori
effect
held
minatoku
tokyo
japan
respons
cytocid
action
cecyd
vitro
antitumor
activ
uiuo
ascertain
howev
whether
antivir
action
cecyd
also
result
inhibitori
effect
ctp
synthetas
present
studi
undertaken
delin
antivir
activ
spectrum
cecyd
comparison
activ
spectrum
ccyd
ii
assess
influenc
exogen
ad
cytidin
nucleosid
antivir
cytocid
action
cecyd
agreement
previou
studi
cecyd
found
highli
potent
inhibitor
viru
replic
tumor
cell
prolifer
prove
activ
remark
broad
rang
rna
dna
virus
antivir
cytocid
action
cecyd
could
revers
cyd
dthd
dcyd
combin
cecyd
pyrazofurin
azauridin
two
compound
known
inhibit
omp
decarboxylas
result
enhanc
cytocid
activ
influenza
type
b
c
cell
cell
line
use
antivir
activ
assay
prk
primari
rabbit
kidney
hel
human
embryon
lung
fibroblast
hela
human
epitheli
cell
line
deriv
cervix
carcinoma
vero
simian
fibroblast
cell
line
deriv
african
green
monkey
kidney
human
embryon
lung
fibroblast
mdck
madindarbi
canin
kidney
ehsm
human
embryon
skinmuscl
fibroblast
rabbit
kidney
cell
line
simian
epitheli
cell
line
deriv
african
green
monkey
kidney
gbk
georgia
bovin
kidney
simian
fibroblast
cell
line
deriv
african
green
monkey
kidney
murin
fibroblast
cell
line
origin
deriv
adult
mous
mutagen
methylcholanthren
cell
line
use
cytocid
activ
assay
besid
vero
hela
cell
murin
leukemia
murin
mammari
carcinoma
human
blymphoblast
raji
human
lymphoblast
molt
cell
cell
grown
eagl
mjnimum
essenti
medium
supplement
fetal
calf
serum
antivir
activ
inhibit
virusinduc
cytopathogen
measur
follow
wellestablish
procedur
viral
cytopathogen
assay
viru
inoculum
ccld
permicrotiterwel
cidcorrespond
viru
stock
dilut
prove
infect
cell
cultur
cytomegaloviru
assay
plaqu
format
measur
instead
viral
cytopathogen
assay
viru
inoculum
pfu
plaqu
form
unit
actiuiri
inhibit
host
cell
macromolecul
dna
rna
protein
synthesi
monitor
incorpor
nredzgl
hjdthd
ytocid
activ
inhibit
prolifer
vero
hela
raji
moltjf
cell
assess
exponenti
growth
phase
monitor
count
number
viabl
cell
follow
stain
trypan
blue
procedur
similar
initi
describ
ceil
two
broadspectrum
antivir
agent
neplanocin
ribavirin
wide
varieti
rna
dna
virus
tabl
four
compound
cecyd
show
pronounc
antivir
activ
virus
ie
tkherp
simplex
vaccinia
polio
reo
junin
tacarib
sspe
cecyd
prove
effect
inhibitori
concentr
pgml
wherea
normal
cell
morpholog
alter
concentr
cecyd
activ
virus
sensit
ccyd
addit
cecyd
prove
also
activ
picornavirus
polio
coxsacki
rhino
sensit
ccyd
thu
activ
spectrum
cecyd
includ
major
viru
group
herp
tkherp
simplex
cytomegalo
pox
vaccinia
picorna
polio
data
taken
hosoya
et
al
data
taken
shigeta
et
al
nd
determin
coxsacki
rhino
toga
sindbi
semliki
forest
corona
orthomyxo
influenza
paramyxo
parainfluenza
measl
arena
junin
tacarib
rhabdo
vesicular
stomat
reo
tabl
cecyd
ccyd
also
examin
inhibitori
effect
replic
human
immunodefici
viru
type
hivl
exponentiallygrow
humantlymphocyt
cell
line
cecyd
ccyd
inhibitori
growth
cell
lcso
ngml
respect
inhibitori
hivl
replic
concentr
icki
host
cell
growth
data
shown
antivir
potenc
antivir
agent
may
differ
consider
depend
choic
cell
previous
note
ccyd
ribavirin
evalu
activ
vesicular
stomat
viru
differ
cell
line
contrast
ccyd
ribavirin
howev
cecyd
inhibit
cytopathogen
vesicular
stomat
viru
cell
line
examin
tabl
differ
ccyd
cecyd
particularli
strike
bscla
two
cell
line
cecyd
exhibit
mark
antivir
activ
wherea
ccyd
concentr
cecyd
inhibit
vesicular
stomat
viru
differ
cell
line
rang
pgml
wherea
alter
normal
cell
morpholog
observ
ccyd
concentr
pgml
cecyd
toxic
rest
confluent
cell
monolay
use
antivir
assay
tabl
concentr
howev
cecyd
prove
inhibitori
vero
cell
dna
rna
synthesi
monitor
incorpor
dthd
urd
respect
concentr
ml
respect
tabl
concentr
coincid
loto
loofold
higher
concentr
cecyd
exhibit
antivir
activ
vero
cell
tabl
yet
point
macromolecul
synthesi
cell
exponenti
growth
phase
wherea
rest
confluent
antivir
activ
assay
cecyd
prove
inhibitori
growth
hel
virus
list
tabl
found
suscept
cecyd
obtain
insight
mechan
action
cecyd
cellular
level
revers
effect
exogen
ad
nucleosid
dthd
urd
dcyd
cyd
antivir
cytocid
activ
cecyd
examin
tabl
antivir
assay
carri
four
virus
repres
dna
viru
vaccinia
rna
viru
vesicular
stomat
rna
viru
reo
rna
viru
semliki
forest
group
deoxyribonucleosid
dthd
dcyd
affect
antivir
potenc
cecyd
even
ad
concentr
loopgml
tabl
mark
contrast
ribonucleosid
cyd
lesser
extent
urd
revers
activ
cecyd
virus
test
ad
pgml
cyd
complet
abolish
antivir
activ
cecyd
wherea
urd
caus
reduct
antivir
potenc
increas
icki
even
ad
concentr
pgml
cyd
annihil
activ
cecyd
vaccinia
viru
semliki
forest
viru
wherea
urd
reduc
similar
result
obtain
regard
revers
effect
nucleosid
cytocid
activ
cecyd
tabl
thu
dthd
dcyd
markedli
influenc
inhibitori
effect
dna
polymeras
cytarabin
examin
conjunct
cecyd
wherea
neplanocin
cytarabin
influenc
inhibitori
effect
cecyd
cell
growth
pyrazofurin
gazauridin
potenti
cytotid
activ
cecyd
antimetabolit
valu
mean
f
sd
requir
reduc
cell
prolifer
exponenti
growth
phase
nucleosid
analogu
effect
reduct
growth
cell
follow
concentr
pyrazofurin
pgml
pg
ml
pgml
neplanocin
pgml
cytarabin
ng
ml
use
concentr
lcso
cell
growth
tabl
condit
pyrazofurin
ad
concentr
ugml
lcso
cell
growth
brought
lofold
decreas
lcso
cecyd
variou
enzym
viral
cellular
origin
shown
interact
either
activ
target
antivir
agent
activ
spectrum
antivir
agent
determin
enzym
interact
exampl
acyclovir
guanin
need
phosphoryl
virusencod
thymidin
kinas
tk
interact
chain
termin
viral
dna
polymeras
henc
acyclovir
activ
virus
particular
herp
simplex
viru
type
encod
viral
tk
recogn
acyclovir
substrat
phosphonylmethoxyalkyl
deriv
ie
hpmpa
adenin
hpmpc
l
cytosin
depend
viral
tk
phosphoryl
henc
compound
effect
much
broader
spectrum
virus
includ
tkherpesvirus
variou
dna
virus
ie
adeno
pox
iridoand
hepadnavirus
compound
recogn
select
antivir
agent
interact
specif
viral
protein
ie
influenza
viru
matrix
protein
amantadin
dna
polymeras
acyclovir
triphosph
hivl
revers
transcriptas
azidothymidin
triphosph
yet
target
protein
necessarili
viral
origin
certain
condit
host
cell
enzym
may
serv
target
antivir
agent
thu
target
antihsv
compound
tk
hsvlinfect
cell
thymidyl
synthas
may
import
target
tkhsvlinfect
cell
also
sadenosylhomocystein
sah
hydrolas
anoth
host
cell
enzym
identifi
target
broadspectrum
antivir
action
sever
acycl
carbocycl
adenosin
analogu
includ
neplanocin
deriv
inhibitori
effect
sah
hydrolas
compound
enhanc
intracellular
level
sah
thu
inhibit
transmethyl
reaction
start
sadenosylmethionin
sam
methyl
donor
includ
number
transmethyl
reaction
catalys
virusassoci
methyltransferas
requir
matur
viral
mrna
like
sah
hydrolas
ctp
synthetas
exampl
host
cell
enzym
may
envisag
target
enzym
antivir
agent
ctp
synthetas
catalys
last
step
biosynthesi
pyrimidin
ribonucleosid
convers
utp
ctp
fig
circumstanti
evid
role
ctpsynthetas
target
cytocid
activ
cecyd
demonstr
sever
cell
line
ie
murin
close
correl
cytocid
activ
compound
deplet
ctp
pool
like
due
inhibit
ctp
synthetas
fact
triphosph
ccyd
cecyd
shown
inhibit
ctp
synthetas
ctp
pool
measur
host
cell
ie
prk
hel
vero
use
antivir
assay
howev
surmis
sinc
cell
system
examin
thu
far
ctp
pool
deplet
consequ
cecyd
treatment
may
also
case
cell
use
present
studi
concentr
cecyd
found
effect
inhibit
virusinduc
cytopathogen
vaccinia
viru
concentr
low
pm
tabl
l
caus
signific
reduct
ctp
pool
also
fact
exogen
addit
cyd
urd
dthd
dcyd
revers
antivir
activ
ccyd
cecyd
tabl
support
notion
antivir
action
cytidin
analogu
may
mediat
inhibit
ctp
synthetas
fig
compound
known
exert
antivir
effect
interfer
biosynthesi
pyrimidin
ribonucleotid
two
antimetabolit
suppos
pyrazofurin
compound
target
omp
decarboxylas
fig
whether
target
ctp
synthetas
ccyd
cecyd
omp
decarboxylas
pyrazofurin
four
compound
antitumor
addit
antivir
properti
fact
antitumor
potenti
pyrazofurin
cecyd
consid
attract
initi
develop
drug
may
compound
cecyd
potenti
antitumor
antivir
agent
virus
tumor
cell
impos
similar
requir
essenti
metabolit
growth
one
may
expect
shortag
suppli
metabolit
lead
suppress
viru
growth
tumor
cell
growth
inhibitori
effect
ctp
synthetas
cecyd
abrog
ctp
suppli
need
viru
replic
tumor
cell
growth
consequ
antivir
cytocid
effect
compound
revers
ctp
pool
restor
exogen
addit
cytidin
whether
cecyd
practic
util
treatment
viru
infect
human
remain
establish
could
argu
antitumor
antivir
properti
cecyd
may
mutual
exclus
certainli
case
antivir
antitumor
cytocid
assay
conduct
differ
condit
rest
confluent
cell
antivir
assay
exponenti
grow
cell
cytocid
assay
condit
cecyd
exhibit
antivir
activ
concentr
sever
order
magnitud
lower
concentr
toxic
host
cell
howev
rapidli
grow
cell
use
monitor
antivir
activ
case
hiv
toxic
compound
host
cell
preclud
specif
action
viru
consider
extrapol
vivo
situat
follow
cecyd
use
antivir
drug
proper
condit
conceiv
prevent
toxic
effect
compound
rapidli
grow
cell
ie
bone
marrow
small
intestin
goal
may
well
achiev
sitespecif
deliveri
wherebi
drug
directli
deliv
site
viru
infect
ie
compound
administ
aerosol
treatment
viru
infect
respiratori
tract
similar
recommend
may
made
pyrazofurin
also
exhibit
broadspectrum
antivir
activ
vitro
addit
prove
inhibitori
replic
respiratori
syncyti
viru
rsv
vivo
cotton
rat
given
daili
dose
mgkg
pyrazofurin
may
toxic
system
administr
aerosol
may
prove
particularli
use
treatment
rsv
infect
also
treatment
respiratori
tract
viru
infect
high
potenc
widespectrum
activ
pyrazofurin
cecyd
tabl
orthoand
paramyxovirus
vitro
make
compound
attract
candid
pursuit
effect
chemotherapi
respiratori
viru
infect
cecyd
pyrazofurin
interact
differ
step
biosynthesi
pyrimidin
ribonucleotid
fig
may
act
synergist
combin
combin
pursu
antivir
antitumor
viewpoint
combin
pyrazofurin
cecyd
alreadi
examin
one
tumor
cell
system
ie
tabl
system
pyrazofurin
potenti
cytocid
activ
cecyd
